FAQs
Stock Price Targets
| High | $81.00 |
|---|
| Median | $56.40 |
| Low | $37.00 |
| Average | $55.49 |
| Current Price | $39.69 |
QDEL Stock Price | QuidelOrtho Corp. Stock Quote (U.S.: Nasdaq) | MarketWatch.
What is the stock price forecast for Qdel in 2025? ›
On average, Wall Street analysts predict that Quidelortho's share price could reach $61.60 by Mar 4, 2025. The average Quidelortho stock price prediction forecasts a potential upside of 55.4% from the current QDEL share price of $39.64.
What does QuidelOrtho do? ›
QuidelOrtho unites the strengths of Quidel Corporation and Ortho Clinical Diagnostics, creating a world-leading in vitro diagnostics company with award-winning expertise in immunoassay and molecular testing, clinical chemistry and transfusion medicine.
Is QuidelOrtho a good stock to buy? ›
QuidelOrtho has 44.36% upside potential, based on the analysts' average price target. QuidelOrtho has a conensus rating of Hold which is based on 2 buy ratings, 2 hold ratings and 2 sell ratings. The average price target for QuidelOrtho is $59.00.
Who are the competitors of QuidelOrtho? ›
The main competitors of QuidelOrtho include Neogen (NEOG), Celldex Therapeutics (CLDX), Intellia Therapeutics (NTLA), Myriad Genetics (MYGN), Lantheus (LNTH), Summit Therapeutics (SMMT), Hims & Hers Health (HIMS), Janux Therapeutics (JANX), Indivior (INDV), and Certara (CERT).
Who bought Quidel? ›
Following the effectiveness of a merger involving Quidel that will take place after the effectiveness of the Ortho Scheme Order, Quidel will also become a wholly owned subsidiary of Topco, and Topco will be renamed QuidelOrtho Corporation.
Who did Quidel merge with? ›
In December 2021, San Diego-based Quidel and Ortho Clinical Diagnostics came to an agreement under which the former would acquire the latter for $24.68 per share of common stock, using a combination of cash and newly issued shares in the combined company, representing a 25% premium on Ortho's closing price on Dec.
Why did Quidel acquire Ortho? ›
The transaction provides Quidel with ample whitespace opportunity to capture demand in emerging markets through telehealth technology and digital health capabilities, utilizing Ortho's strong customer relationships and providing greater patient access to point-of-care diagnostic products.
What is the price prediction for gevo stock in 2030? ›
Long-Term Gevo Stock Price Predictions
| Year | Prediction | Change |
|---|
| 2027 | $ 0.169095 | -73.58% |
| 2028 | $ 0.108504 | -83.05% |
| 2029 | $ 0.069625 | -89.12% |
| 2030 | $ 0.044677 | -93.02% |
2 more rowsThe TQQQ ETF holds a buy signal from the short-term Moving Average; at the same time, however, the long-term average holds a general sell signal. Since the longterm average is above the short-term average there is a general sell signal in the ETF giving a more negative forecast for the stock.
What is AAPL projection for 2030? ›
Apple stock prediction for 1 year from now: $ 212.75 (25.23%) Apple stock forecast for 2025: $ 218.35 (27.60%) Apple stock prediction for 2030: $ 738.72 (331.71%)
Why is Quidel stock dropping? ›
QuidelOrtho Corp.'s stock lost about a third of its value Wednesday after the diagnostic-products manufacturer missed its fourth-quarter profit estimate, announced job cuts, and sustained at least one analyst downgrade.
Is Quidel a good company? ›
QuidelOrtho Corporation has an employee rating of 3.4 out of 5 stars, based on 380 company reviews on Glassdoor which indicates that most employees have a good working experience there.
How big is QuidelOrtho? ›
QuidelOrtho
| Company type | Public |
|---|
| Products | Diagnostic healthcare manufacturer |
| Revenue | $534.2 Million(2019) |
| Number of employees | 6,500 |
| Website | quidelortho.com |
7 more rows
